Oppenheimer Maintains Outperformer on UroGen Pharma, Raises Price Target to $50
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Oppenheimer analyst Leland Gershell maintains UroGen Pharma (NASDAQ:URGN) with a Outperformer and raises the price target from $40 to $50.
Oppenheimer analyst Leland Gershell maintains UroGen Pharma (NASDAQ:URGN) with a Outperformer and raises the price target from $40 to $50.